Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 23

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Neoplasm+2

Recruiting

Study Comparing ANV419 and High Dose IL2 in Adoptive Cell Therapy for Patients with Melanoma, Non-Small Cell Lung Cancer, and Cervical Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Vall D Hebron Institute Of Oncology

Non-small cell lung cancer

Recruiting

Study of Repotrectinib for Frail or Elderly Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Rearrangement

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer

Conjunctivitis allergic+3

Recruiting

Study on the Effectiveness and Safety of Sublingual MM09 for Patients Aged 12-65 with Allergies to House Dust Mites and Rhinitis/Rhinoconjunctivitis with or without Asthma

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dermatophagoides Farinae Extract
  • Sponsor:Inmunotek S.L.

Peritoneal mesothelioma malignant+1

Recruiting

Study of Tremelimumab for Patients with Unresectable Malignant Mesothelioma

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tremelimumab
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer stage III

Recruiting

Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:TheraOp gGmbH

Pneumothorax

Recruiting

Study on the Effects of Ketoprofen and Drug Combination in Patients Undergoing Pleurodesis Surgery for Pneumothorax

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ketoprofen
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Neonatal respiratory distress syndrome

Recruiting

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Poractant Alfa
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Dyspnoea

Recruiting

Study on the Effects of Inhaled Furosemide and Oral Levodropropizine on Breathing Difficulty in Patients with Advanced Lung Disease

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Furosemide
  • Sponsor:Fakultni Nemocnice Hradec Kralove

Non-small cell lung cancer+1

Recruiting

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Squamous cell carcinoma of the oral cavity+4

Recruiting

Study on the Safety and Effectiveness of Afatinib for Fanconi Anemia Patients with Advanced Squamous Cell Carcinoma in the Oral Cavity, Oropharynx, Hypopharynx, or Larynx

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Ovarian cancer+2

Recruiting

Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tub-040
  • Sponsor:Gilead Sciences Inc.

Squamous cell carcinoma of lung

Recruiting

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.